Project Grant HT94252310842
Award Date
8/15/23
Completion Date
8/14/26
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
The Defense Health Agency awarded The Broad Institute, Inc. a $987,600 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target chromophobe renal cell carcinoma with mono- and bi-paratopic antibody drug conjugates. The award period runs from August 1, 2024 to July 31, 2027. As a non-profit research organization, The Broad Institute will leverage its expertise in genomics, proteomics, and computational biology to conduct this innovative biomedical research...
The Broad Institute, Inc. was awarded a $936,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The four-year award will fund research to define signaling pathways and effective combination therapies to improve outcomes for patients with FGFR2-driven biliary cancer. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
Sloan-Kettering Institute For Cancer Research was awarded a $707,999 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding and overcoming treatment resistance in MDM2-amplified esophageal cancers. The three-year award running from April 1, 2023 to March 31, 2026 will support the Institute's investigation into medical solutions for esophageal cancer on the battlefield by developing strategies...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The Defense Health Agency has awarded a $1,780,000 Project Grant titled "SUPPORTING UNDERREPRESENTED POPULATIONS IN GENOMICS-BASED CANCER TRIAL ENROLLMENT (SURGE)" to the Dana-Farber Cancer Institute, Inc. in Boston, MA. This award, funded through the Military Medical Research and Development program (CFDA 12.420), will support cancer research focused on improving enrollment of underrepresented populations in genomics-based clinical trials. The grant period runs from July 1, 2024 to...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,774,998.00 to the Coriell Institute for Medical Research, Inc., a non-profit biomedical research center, to conduct research on exosomal galectin-3 mediated stromal activation and immunosuppression in advanced gastric adenocarcinoma. The award, effective from September 30, 2024 to September 29, 2027, supports the institute's innovative scientific...
The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
The Defense Health Agency awarded a $1,412,826 Project Grant on September 1, 2023 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research through the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "Identification of Risk and Early Detection Biomarkers for Liver Cancer," will support a 3-year study led by Dr. Towia Libermann at Bidmc, with a sub-award to Vanderbilt University Medical Center (VUMC) to assist with case...